Antibiotic Susceptibility of Borrelia burgdorferi In Vitro and In Vivo

Preac-Mursic, V.

doi:10.1007/978-3-642-77614-4_22

Cited by 12 publications

(10 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients: Consecutive adult patients (18 years or older) with typical solitary erythema migrans, treated either with azithromycin or doxycycline and followed up for 1 year were included. All the patients presented in this report were seen by at least one of the authors of this report prior to treatment, 14 days later, 2 months after the first visit, 6 (5.5-6.5) months after the institution of treatment and 12 (11)(12)(13) months after the first visit. Protocols of the studies were approved by the Ethical Committee.…”

Section: Methodsmentioning

confidence: 89%

“…Azithromycin has favourable pharmacokinetic properties [20,21] with intracellular penetration and activity [22] and excellent in vitro and in rive activity against B. burgdorferi [6][7][8][9][10][11]. It has not yet been established which antibiotic is the most efficacious.…”

Section: Discussionmentioning

confidence: 99%

“…It usually appears at the site of a tick bite. As indicated by in vitro studies, as well as by in vivo trials in experimental animals, B. burgdorferi is highly sensitive to azithromycin [6][7][8][9][10][11], which has also proved effective in clinical settings [12][13][14][15]; however, results of the clinical studies are not unequivocal [16,17]. Clinical studies have shown that several antibiotics are beneficial in early Lyme borreliosis.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Azithromycin and doxycycline for treatment ofBorrelia culture-positive erythema migrans

et al. 1996

View full text Add to dashboard Cite

Adult patients with typical solitary erythema migrans, participating in prospective therapeutic studies on early Lyme borreliosis at the Lyme borreliosis Outpatient's Clinic, University Department of Infectious Diseases in Ljubljana, in 1991 to 1993, and followed up for 1 year, were included in the study. Only patients who were treated with azithromycin or doxycycline and in whom Borrelia burgdorferi was isolated from the border of the skin lesion prior to institution of antibiotic treatment were selected for presentation in this report. Fifty-eight patients received azithromycin (500 mg twice daily for the first day, followed by 500 mg once daily for 4 days) and 42 patients received doxycycline (100 mg twice daily for 14 days). The median duration of skin lesions after the beginning of treatment was 6.5 (2-30) days in the azithromycin group and 8 (2-35) days in the doxycycline group (non-significant difference). During the follow-up of 12 months one patient in each group developed major later manifestations of Lyme borreliosis and in 19 patients minor manifestations appeared: in nine (15.5%) treated with azithromycin and in ten (23.8%) receiving doxycycline. In one patient in the azithromycin group and in one patient in the doxycycline group B. burgdorferi was isolated from normal appearing skin at the site of previous erythema migrans 2 months after the institution of antibiotic therapy. Five (8.6%) patients receiving azithromycin and nine (21.4%) patients receiving doxycycline reported mild to moderate gastrointestinal discomfort. In addition, five patients treated with doxycycline developed photosensitivity.

show abstract

Section: Methodsmentioning

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Azithromycin and doxycycline for treatment ofBorrelia culture-positive erythema migrans

et al. 1996

View full text Add to dashboard Cite

show abstract

“…is significantly influenced by the density of the inoculum, the reading mode [17,18,22,25], and the test medium [11,18,[25][26][27]. The inconsistencies outlined above probably account for the wide variability of published MIC and MBC values: for example, the reported MIC of penicillin G varies from 0.003 µg/ml to 8 µg/ml and the MBC from 0.05 µg/ml to > 50 µg/ml [11,22,[28][29][30]. Similarly, for doxycycline, the MIC varies from 0.06 µg/ml to 2 µg/ml and the MBC from 0.25 µg/ml to 6.4 µg/ml [11,19,22,28,29].…”

Section: What We Know: In Vitro Susceptibility Testing Of B Burgdorfmentioning

confidence: 98%

Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: What we know, what we don't know, and what we need to know

Hunfeld

Brade

2006

Wien Klin Wochenschr

View full text Add to dashboard Cite

Human Lyme borreliosis is a multisystem disorder that can progress in stages and is transmitted by ticks of the Ixodes ricinus complex infected with the spirochete Borrelia burgdorferi sensu lato. Today, Lyme borreliosis is regarded as the most important human tickborne illness in the northern hemisphere. Soon after the causative agent was correctly identified and successfully isolated in 1982, antibiotic treatment was shown to be effective and since then a variety of in vitro and in vivo studies have been performed to further characterize the activity of antimicrobial agents against B. burgdorferi s.l. Although many antimicrobial agents have been tested for their in vitro activity against borreliae, the full spectrum of antibiotic susceptibility in B. burgdorferi s.l. has not been defined for many compounds. Moreover, our current understanding of possible antimicrobial resistance mechanisms in B. burgdorferi s.l. is limited and is largely founded on in vitro experiments on relatively few borrelial isolates. This review will summarize what is and what is not known about antimicrobial resistance in B. burgdorferi s.l. and will discuss open questions that continue to fuel the current debate on treatment-resistant Lyme borreliosis.

show abstract

“…4,[8][9][10][11][12][13][14][15][16] In North America and Europe, the antibiotics usually recommended for the treatment of Lyme borreliosis are amoxicillin, doxycycline, erythromycin, penicillin G, minocycline, and ceftriaxone. 17 Recently, Fujita et al 18 demonstrated that minocycline and amoxicillin were effective for eliminating Japanese B. garinii infection in mice, and they recommended the use of these agents for the treatment of patients with Lyme disease in Japan.…”

Section: Introductionmentioning

confidence: 98%

In-vitro and in-vivo antibiotic susceptibilities of Lyme disease Borrelia isolated in China

Masuzawa

Wang

et al. 2000

Journal of Infection and Chemotherapy

View full text Add to dashboard Cite

Antibiotic Susceptibility of Borrelia burgdorferi In Vitro and In Vivo

Cited by 12 publications

References 42 publications

Azithromycin and doxycycline for treatment ofBorrelia culture-positive erythema migrans

Azithromycin and doxycycline for treatment ofBorrelia culture-positive erythema migrans

Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: What we know, what we don't know, and what we need to know

In-vitro and in-vivo antibiotic susceptibilities of Lyme disease Borrelia isolated in China

Contact Info

Product

Resources

About